One Shot Restores Hearing in Weeks for Deaf Patients

A single injection has given ten people born deaf the ability to hear again, marking a breakthrough that researchers are calling life-changing.

The gene therapy targets a specific genetic mutation responsible for a form of inherited deafness. Patients ranging from toddlers to young adults all experienced improved hearing after the treatment, with no serious side effects reported.

The trial took place at five hospitals in China and included patients ages 1 to 24. All participants had mutations in the OTOF gene, which prevents the body from making otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain.

Researchers delivered a working copy of the OTOF gene directly into the inner ear using a single injection. They used a synthetic virus as a delivery vehicle, targeting a membrane at the base of the cochlea called the round window.

Results came quickly. Most patients began regaining hearing within one month, and after six months, every participant showed clear improvement.

The average sound detection level improved dramatically, from 106 decibels to 52 decibels. For context, that's the difference between needing a chainsaw-level noise to hear anything and being able to detect normal conversation.

Children between five and eight years old responded most strongly to the treatment. One seven-year-old girl regained nearly full hearing and could have everyday conversations with her mother just four months after receiving the injection.

Even adult patients showed meaningful improvement. This marks the first time gene therapy for this type of deafness has been successfully tested in teenagers and adults, not just young children.

The Ripple Effect

Dr. Maoli Duan from Karolinska Institutet in Sweden, one of the study's lead researchers, says this is just the beginning. His team is already expanding their work to target other genes that cause deafness, including GJB2 and TMC1, which are more common but also more complex to treat.

Animal studies for these other genetic forms of deafness have shown promising early results. The researchers are confident that many more people with different types of genetic hearing loss will one day have access to similar treatments.

The therapy proved safe and well-tolerated across all age groups. The most common side effect was a temporary decrease in neutrophils, a type of white blood cell, but no serious adverse reactions occurred during the 6 to 12-month follow-up period.

Researchers will continue monitoring these patients to determine how long the hearing improvements last. The findings, published in Nature Medicine, represent years of collaboration between institutions in Sweden and China.

For families affected by genetic deafness, this breakthrough offers something that seemed impossible just a few years ago: the chance to hear the world around them.